key: cord-0043577-xpjyojqy
authors: nan
title: Risk of Covid-19 with renin-angiotensin-aldosterone system medications
date: 2020-05-16
journal: Reactions Weekly
DOI: 10.1007/s40278-020-78440-2
sha: 99b95c5407134de11acde6524b137b5ccf927968
doc_id: 43577
cord_uid: xpjyojqy

nan

The observational study 2 included 12 594 patients in the New York University Langone Health electronic health record with Covid-19 test results between 1 March 2020 and 15 April 2020. There were 5894 positive tests (46.8%), and 1002 patients (17.0%) with severe illness, as indicated by ICU admission (n=726), mechanical ventilation (n=311) and death (n=447). Of the 4357 patients with a history of hypertension, 2573 patients (59.1%) had positive test results and 634 patients (24.6%) had severe illness, as indicated by ICU admission (n=422), mechanical ventilation (n=165) and death (n=343).

In the propensity score-matched cohorts with hypertension, there were no significant associations between the likelihood of a positive Covid-19 test and previous treatment with ACE inhibitors (median difference 0.1%; 95% CI -4.3%, 4.5%) or ARBs (1.6%; -2.6%, 5.8%) compared with untreated patients. In addition, there were no significant associations with other antihypertensive drug classes.

There was no substantially increased risk of serious illness compared with untreated patients (≥10%) in those who had received ACE inhibitors (-3.3%; -8.2%, 1.7%) or ARBs (0.1%, -4.8%, 4.9%). There was a slightly higher risk in patients who had received calcium-channel blockers (4.4%; 0.5%, 8.2%), but no differences in recipients of other antihypertensive drug classes.

"Our findings may help to allay concerns on the part of patients and providers regarding the continued use of these agents in patients undergoing testing or receiving treatment for Covid-19", note the authors.

Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19

Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19

Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19

Adis © 2020 Springer Nature Switzerland AG. All rights reserved

In an accompanying editorial reported in the NEJM, 3 John Jarcho (Boston University) and colleagues note that they "find it reassuring" that the study results "arrive at the consistent message that the continued use of ACE inhibitors and ARBs is unlikely to be harmful in patients with Covid-19". In addition, "the data from these studies support" the recommendation of professional scientific societies and experts that "patients should not discontinue ACE inhibitor or ARB therapy out of a concern that they are at increased risk for infection, severe illness, or death during the Covid-19 pandemic".